Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Marchand Website

Christophe Marchand, Ph.D.

Selected Publications

1)  Pommier Y, Huang SY, Gao R, Das BB, Murai J, Marchand C.
Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).
DNA Repair (Amst.). 19: 114-29, 2014.
[Journal]
2)  Métifiot M, Marchand C, Pommier Y.
HIV integrase inhibitors: 20-year landmark and challenges.
Adv. Pharmacol. 67: 75-105, 2013.
[Journal]
3)  Pommier Y, Marchand C.
Interfacial inhibitors: targeting macromolecular complexes.
Nat Rev Drug Discov. 11: 25-36, 2012.
[Journal]
4)  Huang SN, Pommier Y, Marchand C.
Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors.
Expert Opin Ther Pat. 21: 1285-92, 2011.
[Journal]
5)  Marchand C.
The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
Expert Opin Investig Drugs. 21: 901-4, 2012.
[Journal]
6)  Zhao XZ, Smith SJ, Métifiot M, Marchand C, Boyer PL, Pommier Y, Hughes SH, Burke TR.
4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1.
J. Med. Chem. 2014.
[Journal]
7)  Costi R, Métifiot M, Chung S, Cuzzucoli Crucitti G, Maddali K, Pescatori L, Messore A, Madia VN, Pupo G, Scipione L, Tortorella S, Di Leva FS, Cosconati S, Marinelli L, Novellino E, Le Grice SF, Corona A, Pommier Y, Marchand C, Di Santo R.
Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.
J. Med. Chem. 57: 3223-34, 2014.
[Journal]
8)  Zhao XZ, Smith SJ, Métifiot M, Johnson BC, Marchand C, Pommier Y, Hughes SH, Burke TR.
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
J. Med. Chem. 57: 1573-82, 2014.
[Journal]
9)  Lv PC, Agama K, Marchand C, Pommier Y, Cushman M.
Design, Synthesis, and Biological Evaluation of O-2-Modified Indenoisoquinolines as Dual Topoisomerase I-Tyrosyl-DNA Phosphodiesterase I Inhibitors.
J. Med. Chem. 57: 4324-36, 2014.
[Journal]
10)  Murai J, Marchand C, Shahane SA, Sun H, Huang R, Zhang Y, Chergui A, Ji J, Doroshow JH, Jadhav A, Takeda S, Xia M, Pommier Y.
Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.
DNA Repair (Amst.). 2014.
[Journal]
11)  Gao R, Schellenberg MJ, Huang SY, Abdelmalak M, Marchand C, Nitiss KC, Nitiss JL, Williams RS, Pommier Y.
Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2-DNA and -RNA Covalent Complexes by Tyrosyl-DNA-phosphodiesterase 2 (TDP2).
J. Biol. Chem. 2014.
[Journal]
12)  Beck DE, Agama K, Marchand C, Chergui A, Pommier Y, Cushman M.
Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776).
J. Med. Chem. 57: 1495-512, 2014.
[Journal]
13)  Costi R, Métifiot M, Esposito F, Cuzzucoli Crucitti G, Pescatori L, Messore A, Scipione L, Tortorella S, Zinzula L, Novellino E, Pommier Y, Tramontano E, Marchand C, Di Santo R.
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
J. Med. Chem. 56: 8588-98, 2013.
[Journal]
14)  Métifiot M, Maddali K, Johnson BC, Hare S, Smith SJ, Zhao XZ, Marchand C, Burke TR, Hughes SH, Cherepanov P, Pommier Y.
Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.
ACS Chem. Biol. 8: 209-17, 2013.
[Journal]
15)  Taliani S, Pugliesi I, Barresi E, Salerno S, Marchand C, Agama K, Simorini F, La Motta C, Marini AM, Di Leva FS, Marinelli L, Cosconati S, Novellino E, Pommier Y, Di Santo R, Da Settimo F.
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.
J. Med. Chem. 56: 7458-62, 2013.
[Journal]
16)  Conda-Sheridan M, Reddy PV, Morrell A, Cobb BT, Marchand C, Agama K, Chergui A, Renaud A, Stephen AG, Bindu LK, Pommier Y, Cushman M.
Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).
J. Med. Chem. 56: 182-200, 2013.
[Journal]
17)  Sirivolu VR, Vernekar SK, Marchand C, Naumova A, Chergui A, Renaud A, Stephen AG, Chen F, Sham YY, Pommier Y, Wang Z.
5-Arylidenethioxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase I.
J. Med. Chem. 55: 8671-84, 2012.
[Journal]
18)  Zhao XZ, Maddali K, Smith SJ, Métifiot M, Johnson BC, Marchand C, Hughes SH, Pommier Y, Burke TR.
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.
Bioorg. Med. Chem. Lett. 22: 7309-13, 2012.
[Journal]
19)  Zhao XZ, Maddali K, Metifiot M, Smith SJ, Vu BC, Marchand C, Hughes SH, Pommier Y, Burke TR.
Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
Chem Biol Drug Des. 79: 157-65, 2012.
[Journal]
20)  Gao R, Huang SY, Marchand C, Pommier Y.
Biochemical characterization of human tyrosyl-DNA phosphodiesterase 2 (TDP2/TTRAP): a Mg(2+)/Mn(2+)-dependent phosphodiesterase specific for the repair of topoisomerase cleavage complexes.
J. Biol. Chem. 287: 30842-52, 2012.
[Journal]
21)  Nguyen TX, Morrell A, Conda-Sheridan M, Marchand C, Agama K, Bermingham A, Stephen AG, Chergui A, Naumova A, Fisher R, O'Keefe BR, Pommier Y, Cushman M.
Correction to Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)-Topoisomerase I (Top1) Inhibitors.
J. Med. Chem. 55: 7297, 2012.
[Journal]
22)  Nguyen TX, Morrell A, Conda-Sheridan M, Marchand C, Agama K, Bermingham A, Bermingam A, Stephen AG, Chergui A, Naumova A, Fisher R, O'Keefe BR, Pommier Y, Cushman M.
Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors.
J. Med. Chem. 55: 4457-78, 2012.
[Journal]
23)  Zhao XZ, Maddali K, Metifiot M, Smith SJ, Vu BC, Marchand C, Hughes SH, Pommier Y, Burke TR.
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
Bioorg. Med. Chem. Lett. 21: 2986-90, 2011.
[Journal]
24)  Métifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y.
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
AIDS. 25: 1175-8, 2011.
[Journal]
25)  Métifiot M, Johnson B, Smith S, Zhao XZ, Marchand C, Burke T, Hughes S, Pommier Y.
MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
Antimicrob. Agents Chemother. 55: 5127-33, 2011.
[Journal]
26)  Liao C, Marchand C, Burke TR, Pommier Y, Nicklaus MC.
Authentic HIV-1 integrase inhibitors.
Future Med Chem. 2: 1107-22, 2010.
[Journal]
27)  Métifiot M, Maddali K, Naumova A, Zhang X, Marchand C, Pommier Y.
Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
Biochemistry. 49: 3715-22, 2010.
[Journal]
28)  Pommier Y, Leo E, Zhang H, Marchand C.
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Chem. Biol. 17: 421-33, 2010.
[Journal]
29)  Michelini Z, Galluzzo CM, Negri DR, Leone P, Amici R, Bona R, Summa V, Di Santo R, Costi R, Pommier Y, Marchand C, Palmisano L, Vella S, Cara A.
Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay.
J. Virol. Methods. 168: 272-6, 2010.
[Journal]
30)  Weidlich IE, Dexheimer T, Marchand C, Antony S, Pommier Y, Nicklaus MC.
Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores.
Bioorg. Med. Chem. 18: 182-9, 2010.
[Journal]
31)  Métifiot M, Marchand C, Maddali K, Pommier Y.
Resistance to integrase inhibitors.
Viruses. 2: 1347-66, 2010.
[Journal]
32)  Dexheimer TS, Gediya LK, Stephen AG, Weidlich I, Antony S, Marchand C, Interthal H, Nicklaus M, Fisher RJ, Njar VC, Pommier Y.
4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors.
J. Med. Chem. 52: 7122-31, 2009.
[Journal]
33)  Zhao XZ, Maddali K, Marchand C, Pommier Y, Burke TR.
Diketoacid-genre HIV-1 integrase inhibitors containing enantiomeric arylamide functionality.
Bioorg. Med. Chem. 17: 5318-24, 2009.
[Journal]
34)  Zhao XZ, Maddali K, Vu BC, Marchand C, Hughes SH, Pommier Y, Burke TR.
Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones.
Bioorg. Med. Chem. Lett. 19: 2714-7, 2009.
[Journal]
35)  Marchand C, Maddali K, Métifiot M, Pommier Y.
HIV-1 IN inhibitors: 2010 update and perspectives.
Curr Top Med Chem. 9: 1016-37, 2009.
[Journal]
36)  Marchand C, Lea WA, Jadhav A, Dexheimer TS, Austin CP, Inglese J, Pommier Y, Simeonov A.
Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay.
Mol. Cancer Ther. 8: 240-8, 2009.
[Journal]
37)  Zhao XZ, Semenova EA, Vu BC, Maddali K, Marchand C, Hughes SH, Pommier Y, Burke TR.
2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors.
J. Med. Chem. 51: 251-9, 2008.
[Journal]
38)  Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y.
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Biochemistry. 47: 9345-54, 2008.
[Journal]
39)  Semenova EA, Marchand C, Pommier Y.
HIV-1 integrase inhibitors: update and perspectives.
Adv. Pharmacol. 56: 199-228, 2008.
[Journal]
40)  Marchand C, Beutler JA, Wamiru A, Budihas S, Möllmann U, Heinisch L, Mellors JW, Le Grice SF, Pommier Y.
Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H.
Antimicrob. Agents Chemother. 52: 361-4, 2008.
[Journal]
41)  Di Santo R, Costi R, Roux A, Miele G, Crucitti GC, Iacovo A, Rosi F, Lavecchia A, Marinelli L, Di Giovanni C, Novellino E, Palmisano L, Andreotti M, Amici R, Galluzzo CM, Nencioni L, Palamara AT, Pommier Y, Marchand C.
Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, and biological activities.
J. Med. Chem. 51: 4744-50, 2008.
[Journal]
42)  Dexheimer TS, Antony S, Marchand C, Pommier Y.
Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy.
Anticancer Agents Med Chem. 8: 381-9, 2008.
[Journal]
43)  Antony S, Marchand C, Stephen AG, Thibaut L, Agama KK, Fisher RJ, Pommier Y.
Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1.
Nucleic Acids Res. 35: 4474-84, 2007.
[Journal]
44)  Johnson AA, Marchand C, Patil SS, Costi R, Di Santo R, Burke TR, Pommier Y.
Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays.
Mol. Pharmacol. 71: 893-901, 2007.
[Journal]
45)  Liao C, Karki RG, Marchand C, Pommier Y, Nicklaus MC.
Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA.
Bioorg. Med. Chem. Lett. 17: 5361-5, 2007.
[Journal]
46)  Marchand C, Antony S, Kohn KW, Cushman M, Ioanoviciu A, Staker BL, Burgin AB, Stewart L, Pommier Y.
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Mol. Cancer Ther. 5: 287-95, 2006.
[Journal]
47)  Marchand C, Krajewski K, Lee HF, Antony S, Johnson AA, Amin R, Roller P, Kvaratskhelia M, Pommier Y.
Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites.
Nucleic Acids Res. 34: 5157-65, 2006.
[Journal]
48)  Bona R, Andreotti M, Buffa V, Leone P, Galluzzo CM, Amici R, Palmisano L, Mancini MG, Michelini Z, Di Santo R, Costi R, Roux A, Pommier Y, Marchand C, Vella S, Cara A.
Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds.
Antimicrob. Agents Chemother. 50: 3407-17, 2006.
[Journal]
49)  Semenova EA, Johnson AA, Marchand C, Pommier Y.
Integration of human immunodeficiency virus as a target for antiretroviral therapy.
Curr Opin HIV AIDS. 1: 380-7, 2006.
[Journal]
50)  Johnson AA, Santos W, Pais GC, Marchand C, Amin R, Burke TR, Verdine G, Pommier Y.
Integration requires a specific interaction of the donor DNA terminal 5"-cytosine with glutamine 148 of the HIV-1 integrase flexible loop.
J. Biol. Chem. 281: 461-7, 2006.
[Journal]
51)  Marchand C, Johnson AA, Semenova E, Pommier Y.
Mechanisms and inhibition of HIV integration.
Drug Discov Today Dis Mech. 3: 253-260, 2006.
[Journal]
52)  Di Santo R, Costi R, Roux A, Artico M, Lavecchia A, Marinelli L, Novellino E, Palmisano L, Andreotti M, Amici R, Galluzzo CM, Nencioni L, Palamara AT, Pommier Y, Marchand C.
Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action.
J. Med. Chem. 49: 1939-45, 2006.
[Journal]
53)  Semenova EA, Johnson AA, Marchand C, Davis DA, Yarchoan R, Pommier Y.
Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones.
Mol. Pharmacol. 69: 1454-60, 2006.
[Journal]
54)  Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, Agama K, Nitiss JL, Redon C.
Repair of topoisomerase I-mediated DNA damage.
Prog. Nucleic Acid Res. Mol. Biol. 81: 179-229, 2006.
[Journal]
55)  Di Santo R, Costi R, Artico M, Ragno R, Greco G, Novellino E, Marchand C, Pommier Y.
Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity.
Farmaco. 60: 409-17, 2005.
[Journal]
56)  Pommier Y, Johnson AA, Marchand C.
Integrase inhibitors to treat HIV/AIDS.
Nat Rev Drug Discov. 4: 236-48, 2005.
[Journal]
57)  Pommier Y, Marchand C.
Interfacial inhibitors of protein-nucleic acid interactions.
Curr Med Chem Anticancer Agents. 5: 421-9, 2005.
[Journal]
58)  Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, Pommier Y, Burke TR, Pathak VK.
Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
J. Virol. 78: 3210-22, 2004.
[Journal]
59)  Zhang X, Marchand C, Pommier Y, Burke TR.
Design and synthesis of photoactivatable aryl diketo acid-containing HIV-1 integrase inhibitors as potential affinity probes.
Bioorg. Med. Chem. Lett. 14: 1205-7, 2004.
[Journal]
60)  Johnson AA, Marchand C, Pommier Y.
HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial.
Curr Top Med Chem. 4: 1059-77, 2004.
[Journal]
61)  Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP.
Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.
Bioorg. Med. Chem. Lett. 14: 5595-8, 2004.
[Journal]
62)  Zhang X, Pais GC, Svarovskaia ES, Marchand C, Johnson AA, Karki RG, Nicklaus MC, Pathak VK, Pommier Y, Burke TR.
Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors.
Bioorg. Med. Chem. Lett. 13: 1215-9, 2003.
[Journal]
63)  Krajewski K, Long YQ, Marchand C, Pommier Y, Roller PP.
Design and synthesis of dimeric HIV-1 integrase inhibitory peptides.
Bioorg. Med. Chem. Lett. 13: 3203-5, 2003.
[Journal]
64)  Marchand C, Johnson AA, Karki RG, Pais GC, Zhang X, Cowansage K, Patel TA, Nicklaus MC, Burke TR, Pommier Y.
Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S).
Mol. Pharmacol. 64: 600-9, 2003.
[Journal]
65)  Marchand C, Pourquier P, Laco GS, Jing N, Pommier Y.
Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides.
J. Biol. Chem. 277: 8906-11, 2002.
[Journal]
66)  Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR, Pommier Y.
Structural determinants for HIV-1 integrase inhibition by beta-diketo acids.
J. Biol. Chem. 277: 12596-603, 2002.
[Journal]
67)  Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, Burke TR.
Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors.
J. Med. Chem. 45: 3184-94, 2002.
[Journal]
68)  Marchand C, Neamati N, Pommier Y.
In vitro human immunodeficiency virus type 1 integrase assays.
Meth. Enzymol. 340: 624-33, 2001.
[Journal]
69)  Jing N, Marchand C, Guan Y, Liu J, Pallansch L, Lackman-Smith C, De Clercq E, Pommier Y.
Structure-activity of inhibition of HIV-1 integrase and virus replication by G-quartet oligonucleotides.
DNA Cell Biol. 20: 499-508, 2001.
[Journal]
70)  Marchand C, Nguyen CH, Ward B, Sun JS, Bisagni E, Garestier T, Hélène C.
A new family of sequence-specific DNA-cleaving agents directed by triple-helical structures: benzopyridoindole-EDTA conjugates.
Chemistry. 6: 1559-63, 2000.
[Journal]
71)  Neamati N, Marchand C, Pommier Y.
HIV-1 integrase inhibitors: past, present, and future.
Adv. Pharmacol. 49: 147-65, 2000.
[Journal]
72)  Jing N, Marchand C, Liu J, Mitra R, Hogan ME, Pommier Y.
Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in Vitro.
J. Biol. Chem. 275: 21460-7, 2000.
[Journal]
73)  Pilon AA, Marchand C, Kavlick MF, Bajaj K, Owen J, Mitsuya H, Pommier Y.
Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine.
AIDS Res. Hum. Retroviruses. 16: 1417-22, 2000.
[Journal]
74)  Pommier Y, Marchand C, Neamati N.
Retroviral integrase inhibitors year 2000: update and perspectives.
Antiviral Res. 47: 139-48, 2000.
[Journal]
75)  Pluymers W, Neamati N, Pannecouque C, Fikkert V, Marchand C, Burke TR, Pommier Y, Schols D, De Clercq E, Debyser Z, Witvrouw M.
Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
Mol. Pharmacol. 58: 641-8, 2000.
[Journal]
76)  Zain R, Marchand C, Sun J, Nguyen CH, Bisagni E, Garestier T, Hélène C.
Design of a triple-helix-specific cleaving reagent.
Chem. Biol. 6: 771-7, 1999.
[Journal]
77)  Marchand C, Sun JS, Bailly C, Waring MJ, Garestier T, Hélène C.
Optimization of alternate-strand triple helix formation at the 5"CpG3" and 5"GpC3" junction steps.
Biochemistry. 37: 13322-9, 1998.
[Journal]
78)  Marchand C, Bailly C, Nguyen CH, Bisagni E, Garestier T, Hélène C, Waring MJ.
Stabilization of triple helical DNA by a benzopyridoquinoxaline intercalator.
Biochemistry. 35: 5022-32, 1996.
[Journal]
79)  Bailly C, Marchand C, Hung Nguyen C, Bisagni E, Garestier T, Hélène C, Waring MJ.
Localized chemical reactivity in double-stranded DNA associated with the intercalative binding of benzo[e]pyridoindole and benzo[g]pyridoindole triple-helix-stabilizing ligands.
Eur. J. Biochem. 232: 66-76, 1995.
[Journal]
80)  Zhou BW, Marchand C, Asseline U, Thuong NT, Sun JS, Garestier T, Hélène C.
Recognition of alternating oligopurine/oligopyrimidine tracts of DNA by oligonucleotides with base-to-base linkages.
Bioconjug. Chem. 6: 516-23, 1995.
[Journal]
81)  Marchand C, Bailly C, McLean MJ, Moroney SE, Waring MJ.
The 2-amino group of guanine is absolutely required for specific binding of the anti-cancer antibiotic echinomycin to DNA.
Nucleic Acids Res. 20: 5601-6, 1992.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 7/13/2014.